Post-acute and Chronic Kidney Function Outcomes of COVID-19 in Children and Adolescents: An EHR Cohort Study from the RECOVER Initiative

Lu Li,Ting Zhou,Yiwen Lu,Jiajie Chen,Yuqing Lei,Qiong Wu,Jonathan Arnold,Michael J. Becich,Yuriy Bisyuk,Saul Blecker,Elizabeth Chrischilles,Dimitri A Christakis,Carol Reynolds Geary,Ravi Jhaveri,Leslie Lenert,Mei Liu,Parsa Mirhaji,Hiroki Morizono,Abu Saleh Mohammand Mosa,Ali Mirza Onder,Ruby Patel,William E. Smoyer,Bradley W. Taylor,David A. Williams,Bradley P. Dixon,Joseph T Flynn,Caroline Gluck,Lyndsay A. Harshman,Mark M Mitsnefes,Zubin J. Modi,Cynthia G. Pan,Hiren P. Patel,Priya S. Verghese,Christopher B. Forrest,Michelle R. Denburg,Yong Chen
DOI: https://doi.org/10.1101/2024.06.25.24309488
2024-06-26
Abstract:We investigated the risks of post-acute and chronic adverse kidney outcomes of SARS-CoV-2 infection in the pediatric population via a retrospective cohort study using data from the RECOVER program. We included 1,864,637 children and adolescents under 21 from 19 children's hospitals and health institutions in the US with at least six months of follow-up time between March 2020 and May 2023. We divided the patients into three strata: patients with pre-existing chronic kidney disease (CKD), patients with acute kidney injury (AKI) during the acute phase (within 28 days) of SARS-CoV-2 infection, and patients without pre-existing CKD or AKI. We defined a set of adverse kidney outcomes for each stratum and examined the outcomes within the post-acute and chronic phases after SARS-CoV-2 infection. In each stratum, compared with the non-infected group, patients with COVID-19 had a higher risk of adverse kidney outcomes. For patients without pre-existing CKD, there were increased risks of CKD stage 2+ (HR 1.20; 95% CI: 1.13-1.28) and CKD stage 3+ (HR 1.35; 95% CI: 1.15-1.59) during the post-acute phase (28 days to 365 days) after SARS-CoV-2 infection. Within the post-acute phase of SARS-CoV-2 infection, children and adolescents with pre-existing CKD and those who experienced AKI were at increased risk of progression to a composite outcome defined by at least 50% decline in estimated glomerular filtration rate (eGFR), eGFR <15 mL/min/1.73m2, End Stage Kidney Disease diagnosis, dialysis, or transplant.
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the impact of COVID - 19 infection on renal function outcomes in children and adolescents (under 21 years old) during the post - acute and chronic phases. Specifically, the study aims to assess the risk of new or worsening kidney diseases in children and adolescent patients after SARS - CoV - 2 infection, especially for those without pre - existing chronic kidney disease (CKD), those who experienced acute kidney injury (AKI) during the acute phase, and the patient groups with pre - existing CKD. Through this study, the authors hope to fill the current gaps in the literature on the long - term impact of COVID - 19 on children's kidney health and provide information for future care strategies for affected children. The study used large - scale electronic health record (EHR) data from the RECOVER program, covering data of 1,864,637 children and adolescents from 19 children's hospitals and medical institutions in the United States, with a follow - up time of at least 6 months. The researchers divided the patients into three groups for analysis: 1) patients with pre - existing CKD; 2) patients who experienced AKI during the acute phase (within 28 days) of SARS - CoV - 2 infection; 3) patients without pre - existing CKD or AKI. By evaluating the renal function outcomes of these patients at different stages after SARS - CoV - 2 infection (such as the post - acute phase from 28 days to 365 days and the chronic phase after 365 days), the researchers hope to reveal the specific impact of COVID - 19 on children's kidney health and its long - term consequences.